1. Brugnano, J, McMaster J, Panitch A. Characterization of endocytic uptake of MK-2 inhibitor peptides. J. Pept. Sci. 2013; 19: 629-638.
  2. Brugnano J, Chan B, Seal B, Panitch A. Cell-penetrating peptides can confer biological function: Regulation of inflammatory cytokines in human monocytes by MK2 inhibitor peptides. J. Controlled Release. 2011; 155: 128-133.
  3. Brugnano J, Panitch A. Matrix stiffness affects endocytic uptake of MK2-inhibitor peptides. PLoS One. 2014; 9(1): e84821.
  4. Muto A, Panitch A, Kim N, et al. Inhibition of Mitogen Activated Protein Kinase Activated Protein Kinase II with MMI-0100 Reduces Intimal Hyperplasia ex vivo and in vivo. Vascular Pharmacology. 2012. 56: 47-55.
  5. Vittal R, Fisher A, Gu H, et al. Peptide-mediated inhibition of mitogen-activated protein kinase-activated protein kinase-2 ameliorates bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2013; 49(1): 47-57.
  6. Ward B, Kavalukas S, Brugnano J, et al. Peptide inhibitors of MK2 show promise for inhibition of abdominal adhersions. J Surg Research. 2011; 169(1): e27-e37.
  7. Ward B, Seal B, Brophy C, Panitch A. Design of a bioactive cell-penetrating peptide: when a transduction domain does more than transduce. J. Pept. Sci. 2009; DOI 10.1002/psc. 1168.
MK2 and fibrosis
  1. Cargnello M and Roux P. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol and Molecul Biol Rev. 2011; 75(1): 50-83.
  2. Hagood J and Olman MA. Muscle Fatigue: MK2 signaling and myofibroblast differentiation (Editorial). Am J. Respir Cell Mol Biol. 2007; 37: 503-506.
  3. Liu T, Warburton RR, Guevara OE, Hill NS, Fanburg BL, Gaestel M, Kayyali US. Lack of MK2 inhibits myofibroblast formation and exacerbates pulmonary fibrosis. Am J Respir Cell Mol Biol. 2007 Nov;37(5):507-17.
  4. Sousa AM, Liu T, Guevara O, Stevens J, Fanburg BL, Gaestel M, Toksoz D, Kayyali US. Smooth muscle alpha-actin expression and myofibroblast differentiation by TGFbeta are dependent upon MK2. J Cell Biochem. 2007 Apr 15;100(6):1581-92.
  5. Kapopara PR, von Felden J, Soehnlein O, Wang Y, Napp LC, Sonnenschein K, Wollert KC, Schieffer B, Gaestel M, Bauersachs J, Bavendiek U. Deficiency of MAPK-activated protein kinase 2 (MK2) prevents adverse remodelling and promotes endothelial healing after arterial injury. Thromb Haemost. 2014 Aug 14;112(6).
  6. Thusanth Thuraisingam, Yong Zhong Xu, Kalyn Eadie, Mitra Heravi, Marie-Cristine Guiot, Rony Greemberg, Matthias Gaestel and Danuta Radzioch. MAPKAPK-2 Signaling Is Critical for Cutaneous Wound Healing. Journal of Investigative Dermatology (2010) 130, 278–286; doi:10.1038/jid.2009.209; published online 16 July 2009
General MK2 Articles Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J. Clin Invest. 117: 524-529